Jun 21, 2007 12:00am EDT Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin® technology
Mar 29, 2007 12:00am EDT Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin® in Preclinical Studies
